IN BRIEF: Fresenius SE notes EMA positive recommendation for candidate

Fresenius SE & Co KGaA - Bad Homburg, Germany-based health care company - Says Fresenius Kabi's ...

Alliance News 21 July, 2023 | 12:35PM
Email Form Facebook Twitter LinkedIn RSS

Fresenius SE & Co KGaA - Bad Homburg, Germany-based health care company - Says Fresenius Kabi's tocilizumab biosimilar candidate, MSB11456, has received a positive recommendation for a marketing authorization from the European Medicines Agency's committee for medicinal products for human use. Says MSB11456 becomes the first tocilizumab biosimilar candidate to be granted a positive opinion by the CHMP for the treatment of several autoimmune diseases.

"This achievement marks a significant milestone in Fresenius Kabi's Vision 2026 growth strategy," it adds.

Current stock price: EUR28.27, up 0.5% in Frankfurt on Friday afternoon

12-month change: up 5.0%

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Fresenius SE & Co KGaA 28.15 EUR 0.64

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures